Antineoplastic Agents, Phytogenic
"Antineoplastic Agents, Phytogenic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
| Descriptor ID |
D000972
|
| MeSH Number(s) |
D27.505.954.248.179
|
| Concept/Terms |
Antineoplastic Agents, Phytogenic- Antineoplastic Agents, Phytogenic
- Agents, Phytogenic Antineoplastic
- Phytogenic Antineoplastic Agents
- Antineoplastics, Phytogenic
- Phytogenic Antineoplastics
- Antineoplastics, Botanical
- Botanical Antineoplastics
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Phytogenic".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Phytogenic".
This graph shows the total number of publications written about "Antineoplastic Agents, Phytogenic" by people in this website by year, and whether "Antineoplastic Agents, Phytogenic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2018 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents, Phytogenic" by people in Profiles.
-
A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2018 12; 151(3):422-427.
-
Deciphering the Molecular Mechanism Underlying the Inhibitory Efficacy of Taiwanese Local Pomegranate Peels against Urinary Bladder Urothelial Carcinoma. Nutrients. 2018 Apr 27; 10(5).
-
Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol. 2015 Dec; 35 Suppl:S276-S304.
-
A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study. Gynecol Oncol. 2016 Jan; 140(1):48-52.
-
Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. Oral Oncol. 2012 Oct; 48(10):1025-1030.
-
Identification of genomic regions contributing to etoposide-induced cytotoxicity. Hum Genet. 2009 Mar; 125(2):173-80.
-
Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer. 2008 May 20; 98(10):1608-13.
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007 Dec 27; 357(26):2666-76.
-
Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity. Mol Cancer Ther. 2007 Oct; 6(10):2686-95.
-
Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer. Expert Rev Anticancer Ther. 2007 Apr; 7(4):415-22.